98%
921
2 minutes
20
Background: Early detection of cardiac impairment in overweight and obesity is essential for early preventive strategies against heart failure. Myocardial work is a novel echocardiographic parameter that incorporates left ventricular afterload into global longitudinal strain analysis. This study aimed to: 1) assess subclinical alterations of myocardial work among non-diabetic overweight and obese individuals with normal left ventricular ejection fraction (LVEF); 2) investigate the impact of cardiometabolic traits on these alterations; and 3) determine the correlation between myocardial work and myocardial tissue characteristics.
Methods: In the prospective EARLY-MYO-OBESITY-II study (NCT04933188), we enrolled 150 non-diabetic participants, including 50 obese individuals (BMI ≥ 30 kg/m), 50 age- and gender-matched overweight individuals (BMI 25-30 kg/m), and 50 healthy lean controls (BMI < 25 kg/m). Non-invasive myocardial work was calculated from two-dimensional speckle-tracking echocardiography and cuff blood pressure, while myocardial fibrosis was assessed using extracellular volume fraction (ECV) and native T1 value from cardiac magnetic resonance imaging.
Results: Global work index (GWI) and constructive work (GCW) were decreased in the obese participants compared with the overweight and control groups. Both overweight and obese groups exhibited elevated global wasted work (GWW) and reduced global work efficiency (GWE). In multivariate regression analysis, elevated Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) values were independently associated with reduced GWI and GCW (β = -89.953 and -121.191, respectively). The overweight and obese groups showed elevated ECV and native T1 compared to the control group. GWW and GWE were significantly correlated with ECV (Spearman's Rho 0.516 and -0.547, respectively) and demonstrated superior predictive value for myocardial fibrosis (AUC = 0.86 and 0.82, respectively) compared to global longitudinal strain (AUC = 0.58).
Conclusions: Myocardial work is impaired in non-diabetic overweight and obese individuals, even with preserved LVEF. Insulin resistance is significantly and independently associated with myocardial work, highlighting the importance of targeting individuals with insulin resistance to reduce heart failure risk. Non-invasive myocardial work may serve as an image marker for detecting early cardiac fibrosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijcard.2025.133321 | DOI Listing |
Cardiovasc Revasc Med
August 2025
Department of Cardiothoracic Surgery, NYU Langone Health, NY, United States of America. Electronic address:
Background: Transcatheter aortic valve replacement (TAVR) has become a cornerstone in the management of aortic valve disease. However, delayed complications after hospital discharge and readmission remain in an issue following TAVR. We aimed to evaluate the impact of remote monitoring systems on clinical outcomes after TAVR.
View Article and Find Full Text PDFInt J Cardiol
September 2025
Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197 Rome, Italy.
Introduction: Endurance athletes are expected to present a cardiac remodeling characterized by eccentric hypertrophy. Differentiation from underlying cardiomyopathy mimicking a similar cardiac remodeling may be challenging. Myocardial work indexes (MWI) have been shown to be useful in distinguishing between physiological adaption and pathological changes in the athletes' heart.
View Article and Find Full Text PDFJ Mol Cell Cardiol
September 2025
Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address:
Selective therapeutic targeting of cardiomyocytes (CMs) and non-myocytes (NMs) within the heart is an active field of research. The success of those novel therapeutic strategies is linked to the ability to accurately assess uptake and gene delivery efficiencies in clinically relevant animal models. Nevertheless, quantification at the single cell level remains a significant challenge.
View Article and Find Full Text PDFEur J Pharm Biopharm
September 2025
Drug Research Program, Faculty of Pharmacy, University of Helsinki, Finland; Individualized Drug Therapy Research Program, University of Helsinki, Finland; Wihuri Research Institute, Helsinki, Finland; Helsinki One Health, Helsinki, Finland. Electronic address:
Vascular Endothelial Growth Factor C (VEGFC) is a promising biological drug, with preclinical studies indicating its potential for treating myocardial infarction, neurodegenerative diseases, and lymphedema, a condition that currently lacks curative treatment. While adenoviral VEGFC gene therapy has progressed to phase II studies, its clinical efficacy is limited by rapid immune inactivation. This study explores lignin nanoparticles (LNPs) as an alternative VEGFC delivery system.
View Article and Find Full Text PDFEur J Pharmacol
September 2025
Department of Cardiovascular Surgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University. Electronic address:
Purpose: Ischemia-reperfusion injury remains a major problem following myocardial infarction. Alpinetin (ALPT) has been reported to exhibit cardioprotective effects as well as resistance to ischemia-reperfusion injury. However, its role and mechanism during myocardial ischemia-reperfusion injury are unknown.
View Article and Find Full Text PDF